It looks like we’re in for another round of M&A activity.
According to JP Morgan, AstraZeneca is looking to acquire Shire. We also have rumors of Johnson & Johnson looking at Sepracor. And Amgen is desperately looking for anything to reverse its slide.
However, buying revenue won’t boost pipelines. And that’s the real challenge.
